Rxivist logo

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

By Xiangyu Chen, Ren Li, Zhiwei Pan, Chunfang Qian, Yang Yang, Renrong You, Jing Zhao, Pinghuang Liu, Leiqiong Gao, Zhirong Li, Qizhao Huang, Lifan Xu, Jianfang Tang, Qin Tian, Wei Yao, Li Hu, Xiaofeng Yan, Xinyuan Zhou, Yuzhang Wu, Kai Deng, Zheng Zhang, Zhaohui Qian, Yaokai Chen, Lilin Ye

Posted 11 Apr 2020
medRxiv DOI: 10.1101/2020.04.06.20055475

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel corona virus disease (COVID-19). To date, no prophylactic vaccines or approved therapeutic agents are available for preventing and treating this highly transmittable disease. Here we report two monoclonal antibodies (mAbs) cloned from memory B cells of patients recently recovered from COVID-19, and both mAbs specifically bind to the spike (S) protein of SARS-CoV-2, block the binding of receptor binding domain (RBD) of SARS-CoV-2 to human angiotensin converting enzyme 2 (hACE2), and effectively neutralize S protein-pseudotyped virus infection. These human mAbs hold the promise for the prevention and treatment of the ongoing pandemic of COVID-19.

Download data

  • Downloaded 1,899 times
  • Download rankings, all-time:
    • Site-wide: 9,447
    • In infectious diseases: 1,318
  • Year to date:
    • Site-wide: 43,700
  • Since beginning of last month:
    • Site-wide: 39,521

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide